Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNC-109 in recurrent glioblastoma
NCT05868083Phase 1Unknown
- Sponsor
- Simnova Biotherapeutics
- Start
- Jun 2022
- Primary completion
- May 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SNC-109 in glioblastoma (GBM), sponsored by Simnova Biotherapeutics. Primary endpoints: Incidence of treatment related adverse events at 28 days, Cmax of SNC-109 Cell count at 2 years and 5 more. Status: unknown.
02
Drugs
SNC-109
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05868083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05868083.